Research and Development Update

Paris, France and Camberley, UK – 24 February 2021 – Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, announces an update on the progress of its near-term research and development programmes, including the expansion of its product portfolio, clinical trial activity and the publication of independent validations of the Company’s COVID-19

Visit Page

Launch of PCR genotyping assay portfolio to detect COVID-19 variants

Paris, France and Camberley, UK – 2 February 2021 – Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, announces the launch of a new and innovative portfolio of assays (under the brand name SNPsig®) to aid the diagnosis of the new variants of SARS-CoV-2. http://novacyt.com/wp-content/uploads/2021/02/Novacyt-Variants-launch-02.02.21-ENGLISH.pdf

Visit Page

Full Year 2020 Trading Update

Paris, France and Camberley, UK – 29 January 2021 – Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, announces an unaudited trading update for the year ended 31 December 2020. http://novacyt.com/wp-content/uploads/2021/01/Novacyt-Trading-Update-29.01.2021-ENGLISH.pdf

Visit Page